Harms, benefits and costs of fecal immunochemical testing versus guaiac fecal occult blood testing for colorectal cancer screening

• S. Lucas Goede,

  Affiliation Department of Public Health, Erasmus University Medical Center, Rotterdam, The Netherlands

  ⨯
• Linda Rabeneck,

  Affiliations Prevention and Cancer Control, Cancer Care Ontario, Toronto, Canada, Institute for Clinical Evaluative Sciences, Toronto, Canada, Department of Medicine, University of Toronto, Toronto, Canada

  ⨯
• Marjolein van Ballegooijen,

  Affiliation Department of Public Health, Erasmus University Medical Center, Rotterdam, The Netherlands

  ⨯
• Ann G. Zauber,

  Affiliation Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, United States of America

  ⨯
• Lawrence F. Paszat,

  Affiliation Institute for Clinical Evaluative Sciences, Toronto, Canada

  ⨯
• Jeffrey S. Hoch,

  Affiliations Institute for Clinical Evaluative Sciences, Toronto, Canada, Centre for Excellence in Economic Analysis Research, Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, Canada

  ⨯
• Jean H. E. Yong,

  Affiliation Centre for Excellence in Economic Analysis Research, Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, Canada

  ⨯
• Sonja Kroep,

  Affiliation Department of Public Health, Erasmus University Medical Center, Rotterdam, The Netherlands

  ⨯
• Jill Tinmouth,

  Affiliations Institute for Clinical Evaluative Sciences, Toronto, Canada, Department of Medicine, Division of Gastroenterology, Sunnybrook Health Sciences Centre, Toronto, Canada

  ⨯
• Iris Lansdorp-Vogelaar

  * E-mail: i.vogelaar@erasmusmc.nl

  Affiliation Department of Public Health, Erasmus University Medical Center, Rotterdam, The Netherlands

  ⨯